Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT002 dose-escalation study in healthy volunteers and patients with chronic rhinosinusitis with nasal polyps, with or without asthma
CTR20254506Phase 2Active
- Sponsor
- Bambusa Therapeutics
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BBT002 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Bambusa Therapeutics. Started May 2026; status: active.
02
Drugs
BBT002
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20254506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254506.